Differential epitope mapping of antibodies to PDC-E2 in patients with hematologic malignancies after allogeneic hematopoietic stem cell transplantation and primary biliary cirrhosis

Roberto Bellucci, Sabine Oertelt, Meagan Gallagher, Sigui Li, Emmanuel Zorn, Edie Weller, Fabrice Porcheray, Edwin P. Alyea, Robert J. Soiffer, Nikhil C. Munshi, M. Eric Gershwin, Jerome Ritz

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

A unique characteristic of the autoimmune liver disease primary biliary cirrhosis (PBC) is the presence of high-titer and extremely specific autoantibodies to the E2 component of the pyruvate dehydrogenase complex (PDC-E2). Autoantibodies to PDC-E2 antigen have only been detected in patients with disease or in those who subsequently develop PBC. One exception has been a subgroup of patients with multiple myeloma (MM) who underwent allogeneic hematopoietic stem cell transplantation (HSCT) and received donor lymphocyte infusions (DLIs) after transplantation. These patients developed high-titer antibodies to a variety of myeloma-associated antigens, including PDC-E2, coincident with rejection of myeloma cells in vivo. To examine the specificity of autoantibodies to PDC in these patients, we screened sera from patients with MM, chronic leukemias, monoclonal gammopathy of unknown significance (MGUS), PBC, and healthy donors. Three of 11 patients with MM (27%) and 2 of 6 patients with chronic leukemias (33%) developed anti-PDC-E2 antibodies in association with DLI response; 2 of 12 (17%) patients in the MGUS pretreatment control population also had detectable anti-PDC responses. Interestingly, the epitope specificity of these PDC-E2 autoantibodies was distinctive, suggesting that the mechanisms leading to loss of tolerance in the transplantation patients are distinct from PBC.

Original languageEnglish (US)
Pages (from-to)2001-2007
Number of pages7
JournalBlood
Volume109
Issue number5
DOIs
StatePublished - Mar 1 2007

Fingerprint

Epitope Mapping
Biliary Liver Cirrhosis
Hematopoietic Stem Cell Transplantation
Hematologic Neoplasms
Stem cells
Autoantibodies
Epitopes
Lymphocytes
Antibodies
Pyruvate Dehydrogenase Complex
Multiple Myeloma
Antigens
Paraproteinemias
Tissue Donors
Liver
Leukemia
Dihydrolipoyllysine-Residue Acetyltransferase
Transplantation Tolerance
Autoimmune Diseases
Liver Diseases

ASJC Scopus subject areas

  • Hematology

Cite this

Differential epitope mapping of antibodies to PDC-E2 in patients with hematologic malignancies after allogeneic hematopoietic stem cell transplantation and primary biliary cirrhosis. / Bellucci, Roberto; Oertelt, Sabine; Gallagher, Meagan; Li, Sigui; Zorn, Emmanuel; Weller, Edie; Porcheray, Fabrice; Alyea, Edwin P.; Soiffer, Robert J.; Munshi, Nikhil C.; Gershwin, M. Eric; Ritz, Jerome.

In: Blood, Vol. 109, No. 5, 01.03.2007, p. 2001-2007.

Research output: Contribution to journalArticle

Bellucci, R, Oertelt, S, Gallagher, M, Li, S, Zorn, E, Weller, E, Porcheray, F, Alyea, EP, Soiffer, RJ, Munshi, NC, Gershwin, ME & Ritz, J 2007, 'Differential epitope mapping of antibodies to PDC-E2 in patients with hematologic malignancies after allogeneic hematopoietic stem cell transplantation and primary biliary cirrhosis', Blood, vol. 109, no. 5, pp. 2001-2007. https://doi.org/10.1182/blood-2006-06-030304
Bellucci, Roberto ; Oertelt, Sabine ; Gallagher, Meagan ; Li, Sigui ; Zorn, Emmanuel ; Weller, Edie ; Porcheray, Fabrice ; Alyea, Edwin P. ; Soiffer, Robert J. ; Munshi, Nikhil C. ; Gershwin, M. Eric ; Ritz, Jerome. / Differential epitope mapping of antibodies to PDC-E2 in patients with hematologic malignancies after allogeneic hematopoietic stem cell transplantation and primary biliary cirrhosis. In: Blood. 2007 ; Vol. 109, No. 5. pp. 2001-2007.
@article{4349c34cc34a4ab1974b4a9fb5b62e19,
title = "Differential epitope mapping of antibodies to PDC-E2 in patients with hematologic malignancies after allogeneic hematopoietic stem cell transplantation and primary biliary cirrhosis",
abstract = "A unique characteristic of the autoimmune liver disease primary biliary cirrhosis (PBC) is the presence of high-titer and extremely specific autoantibodies to the E2 component of the pyruvate dehydrogenase complex (PDC-E2). Autoantibodies to PDC-E2 antigen have only been detected in patients with disease or in those who subsequently develop PBC. One exception has been a subgroup of patients with multiple myeloma (MM) who underwent allogeneic hematopoietic stem cell transplantation (HSCT) and received donor lymphocyte infusions (DLIs) after transplantation. These patients developed high-titer antibodies to a variety of myeloma-associated antigens, including PDC-E2, coincident with rejection of myeloma cells in vivo. To examine the specificity of autoantibodies to PDC in these patients, we screened sera from patients with MM, chronic leukemias, monoclonal gammopathy of unknown significance (MGUS), PBC, and healthy donors. Three of 11 patients with MM (27{\%}) and 2 of 6 patients with chronic leukemias (33{\%}) developed anti-PDC-E2 antibodies in association with DLI response; 2 of 12 (17{\%}) patients in the MGUS pretreatment control population also had detectable anti-PDC responses. Interestingly, the epitope specificity of these PDC-E2 autoantibodies was distinctive, suggesting that the mechanisms leading to loss of tolerance in the transplantation patients are distinct from PBC.",
author = "Roberto Bellucci and Sabine Oertelt and Meagan Gallagher and Sigui Li and Emmanuel Zorn and Edie Weller and Fabrice Porcheray and Alyea, {Edwin P.} and Soiffer, {Robert J.} and Munshi, {Nikhil C.} and Gershwin, {M. Eric} and Jerome Ritz",
year = "2007",
month = "3",
day = "1",
doi = "10.1182/blood-2006-06-030304",
language = "English (US)",
volume = "109",
pages = "2001--2007",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "5",

}

TY - JOUR

T1 - Differential epitope mapping of antibodies to PDC-E2 in patients with hematologic malignancies after allogeneic hematopoietic stem cell transplantation and primary biliary cirrhosis

AU - Bellucci, Roberto

AU - Oertelt, Sabine

AU - Gallagher, Meagan

AU - Li, Sigui

AU - Zorn, Emmanuel

AU - Weller, Edie

AU - Porcheray, Fabrice

AU - Alyea, Edwin P.

AU - Soiffer, Robert J.

AU - Munshi, Nikhil C.

AU - Gershwin, M. Eric

AU - Ritz, Jerome

PY - 2007/3/1

Y1 - 2007/3/1

N2 - A unique characteristic of the autoimmune liver disease primary biliary cirrhosis (PBC) is the presence of high-titer and extremely specific autoantibodies to the E2 component of the pyruvate dehydrogenase complex (PDC-E2). Autoantibodies to PDC-E2 antigen have only been detected in patients with disease or in those who subsequently develop PBC. One exception has been a subgroup of patients with multiple myeloma (MM) who underwent allogeneic hematopoietic stem cell transplantation (HSCT) and received donor lymphocyte infusions (DLIs) after transplantation. These patients developed high-titer antibodies to a variety of myeloma-associated antigens, including PDC-E2, coincident with rejection of myeloma cells in vivo. To examine the specificity of autoantibodies to PDC in these patients, we screened sera from patients with MM, chronic leukemias, monoclonal gammopathy of unknown significance (MGUS), PBC, and healthy donors. Three of 11 patients with MM (27%) and 2 of 6 patients with chronic leukemias (33%) developed anti-PDC-E2 antibodies in association with DLI response; 2 of 12 (17%) patients in the MGUS pretreatment control population also had detectable anti-PDC responses. Interestingly, the epitope specificity of these PDC-E2 autoantibodies was distinctive, suggesting that the mechanisms leading to loss of tolerance in the transplantation patients are distinct from PBC.

AB - A unique characteristic of the autoimmune liver disease primary biliary cirrhosis (PBC) is the presence of high-titer and extremely specific autoantibodies to the E2 component of the pyruvate dehydrogenase complex (PDC-E2). Autoantibodies to PDC-E2 antigen have only been detected in patients with disease or in those who subsequently develop PBC. One exception has been a subgroup of patients with multiple myeloma (MM) who underwent allogeneic hematopoietic stem cell transplantation (HSCT) and received donor lymphocyte infusions (DLIs) after transplantation. These patients developed high-titer antibodies to a variety of myeloma-associated antigens, including PDC-E2, coincident with rejection of myeloma cells in vivo. To examine the specificity of autoantibodies to PDC in these patients, we screened sera from patients with MM, chronic leukemias, monoclonal gammopathy of unknown significance (MGUS), PBC, and healthy donors. Three of 11 patients with MM (27%) and 2 of 6 patients with chronic leukemias (33%) developed anti-PDC-E2 antibodies in association with DLI response; 2 of 12 (17%) patients in the MGUS pretreatment control population also had detectable anti-PDC responses. Interestingly, the epitope specificity of these PDC-E2 autoantibodies was distinctive, suggesting that the mechanisms leading to loss of tolerance in the transplantation patients are distinct from PBC.

UR - http://www.scopus.com/inward/record.url?scp=33847419979&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33847419979&partnerID=8YFLogxK

U2 - 10.1182/blood-2006-06-030304

DO - 10.1182/blood-2006-06-030304

M3 - Article

VL - 109

SP - 2001

EP - 2007

JO - Blood

JF - Blood

SN - 0006-4971

IS - 5

ER -